ECSP21002804A - Apirasas solubilizadas, métodos y usos - Google Patents

Apirasas solubilizadas, métodos y usos

Info

Publication number
ECSP21002804A
ECSP21002804A ECSENADI20212804A ECDI202102804A ECSP21002804A EC SP21002804 A ECSP21002804 A EC SP21002804A EC SENADI20212804 A ECSENADI20212804 A EC SENADI20212804A EC DI202102804 A ECDI202102804 A EC DI202102804A EC SP21002804 A ECSP21002804 A EC SP21002804A
Authority
EC
Ecuador
Prior art keywords
solubilized
methods
apirases
preventing
design
Prior art date
Application number
ECSENADI20212804A
Other languages
English (en)
Inventor
Boerje Haraldsson
Regina Link
Guido Junge
Max Warncke
Agostino Cirillo
Thomas Huber
Chao Zou
Hilmar Ebersbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP21002804A publication Critical patent/ECSP21002804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Abstract

La invención se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados, composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.
ECSENADI20212804A 2018-07-18 2021-01-14 Apirasas solubilizadas, métodos y usos ECSP21002804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18

Publications (1)

Publication Number Publication Date
ECSP21002804A true ECSP21002804A (es) 2021-04-29

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20212804A ECSP21002804A (es) 2018-07-18 2021-01-14 Apirasas solubilizadas, métodos y usos

Country Status (26)

Country Link
US (1) US20220356455A1 (es)
EP (1) EP3824079A1 (es)
JP (2) JP7425784B2 (es)
KR (1) KR20210035806A (es)
CN (1) CN112424346A (es)
AR (1) AR115790A1 (es)
AU (1) AU2019306821B2 (es)
BR (1) BR112021000586A2 (es)
CA (1) CA3103684A1 (es)
CL (1) CL2021000129A1 (es)
CO (1) CO2021000210A2 (es)
CR (1) CR20210021A (es)
CU (1) CU20210008A7 (es)
EA (1) EA202190057A1 (es)
EC (1) ECSP21002804A (es)
IL (1) IL280191A (es)
JO (1) JOP20210008A1 (es)
MA (1) MA53177A (es)
MX (1) MX2021000542A (es)
PE (1) PE20210185A1 (es)
PH (1) PH12021550122A1 (es)
SG (1) SG11202011776RA (es)
TW (1) TW202016299A (es)
UY (1) UY38299A (es)
WO (1) WO2020016804A1 (es)
ZA (1) ZA202007187B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157131A1 (en) * 2020-05-28 2023-04-05 Charm Sciences, Inc. Methods and assemblies for sample analysis
WO2024023746A1 (en) 2022-07-29 2024-02-01 Novartis Ag Improved production of cd39 variants
WO2024023745A1 (en) 2022-07-29 2024-02-01 Novartis Ag Treatment for acute organ injury using cd39, recombinant cd39

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023459A1 (en) 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
US8551774B2 (en) 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
US8535662B2 (en) * 2010-01-13 2013-09-17 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions
WO2015092735A1 (en) 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
US11242551B2 (en) 2013-12-20 2022-02-08 Novartis Ag Eukaryotic cells and methods for recombinantly expressing a product of interest

Also Published As

Publication number Publication date
PE20210185A1 (es) 2021-02-02
AU2019306821A1 (en) 2020-12-24
JP2024023297A (ja) 2024-02-21
CN112424346A (zh) 2021-02-26
JP7425784B2 (ja) 2024-01-31
JOP20210008A1 (ar) 2021-01-12
UY38299A (es) 2020-02-28
ZA202007187B (en) 2022-06-29
BR112021000586A2 (pt) 2021-04-06
JP2021529550A (ja) 2021-11-04
MA53177A (fr) 2021-05-26
IL280191A (en) 2021-03-01
CA3103684A1 (en) 2020-01-23
CR20210021A (es) 2021-03-23
TW202016299A (zh) 2020-05-01
EA202190057A1 (ru) 2021-08-24
CL2021000129A1 (es) 2021-08-20
SG11202011776RA (en) 2021-02-25
MX2021000542A (es) 2021-03-29
WO2020016804A1 (en) 2020-01-23
EP3824079A1 (en) 2021-05-26
CU20210008A7 (es) 2021-08-06
US20220356455A1 (en) 2022-11-10
AU2019306821B2 (en) 2022-09-29
KR20210035806A (ko) 2021-04-01
CO2021000210A2 (es) 2021-01-18
AR115790A1 (es) 2021-02-24
PH12021550122A1 (en) 2021-09-27

Similar Documents

Publication Publication Date Title
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
SV2018005610A (es) Derivados de oxopiridina sustituidos
UY37480A (es) Nuevos derivados de quinolina
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37831A (es) Nuevos derivados de quinolina
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CL2016002389A1 (es) Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros.
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer